HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[The efficacy of granisetron as a prophylactic anti-emetic agent used in conjunction with MCNU and VP16 chemotherapeutic regimens in the management of a pediatric case of hypothalamic anaplastic astrocytoma].

Abstract
The management of a 12-year-old boy with hypothalamic anaplastic astrocytoma is reported herein. The pediatric patient underwent a subtotal removal of his brain tumor, and subsequently received multimodal treatment comprising radiotherapy (30.6 Gy to the whole brain and 50.4 Gy to the local lesion) and immunochemotherapy with MCNU (80 mg/m2, day 1), VP 16 (50 mg/day, days 2 to 6), and interferon-beta (3 x 10(6) units/day, initiating on day 2 for 4 weeks). The immunochemotherapy was given as of 4 weeks after radiotherapy. The administration of anti-cancer drugs caused severe nausea and vomiting, the intra-carotid infusion of MCNU being particularly emetogenic. The multi-modal treatment was then discontinued for a few weeks. A partial response was obtained, and the patient subsequently received 3 courses of maintenance therapy at six-month intervals using the same protocol as for the initial immunochemotherapy. During maintenance therapy, granisetron (40 micrograms/kg) was given intravenously 30 minutes before and one day after the injection of MCNU. Owing to the anti-emetic management of this patient, there were no complications throughout the chemotherapy. The patient has now survived for more than 3 years with a good quality of life, showing a Karnofsky performance score of 90.
AuthorsT Yamasaki, S Konishi, T Kagawa, H Nagai, S Nagao, K Moritake
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 22 Issue 10 Pg. 1397-402 (Sep 1995) ISSN: 0385-0684 [Print] Japan
PMID7668877 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Nitrosourea Compounds
  • Etoposide
  • Interferon-beta
  • ranimustine
  • Granisetron
Topics
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Child
  • Combined Modality Therapy
  • Etoposide (administration & dosage)
  • Glioblastoma (drug therapy, radiotherapy, surgery)
  • Granisetron (therapeutic use)
  • Humans
  • Hypothalamic Neoplasms (drug therapy, radiotherapy, surgery)
  • Interferon-beta (administration & dosage)
  • Male
  • Nausea (prevention & control)
  • Nitrosourea Compounds (adverse effects)
  • Vomiting (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: